US 10711029
Beta-d-2′-deoxy-2′-alpha-fluoro-2′-beta-c-substituted-4′fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection
granted A61PA61P31/14
Quick answer
US patent 10711029 (Beta-d-2′-deoxy-2′-alpha-fluoro-2′-beta-c-substituted-4′fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection) held by Atea Pharmaceuticals, Inc. expires Mon Jul 09 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Atea Pharmaceuticals, Inc.
- Grant date
- Tue Jul 14 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jul 09 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 32
- CPC classes
- A61P, A61P31/14